274
Participants
Start Date
April 12, 2020
Primary Completion Date
March 4, 2021
Study Completion Date
May 12, 2021
Non Interventional study
Non Interventional study
Barmherzige Brüder Krankenhaus St. Veit/Glan., Saint Veit/Glan
Medizinische Universität Wien, Vienna
Imelda VZW, Bonheiden
AZ Klina, Brasschaat
UZ Leuven, Leuven
CHC MontLégia, Liège
CHRU de Besançon, Besançon
GHPSO (Groupe Hospitalier Sud de l'Oise), Creil
CHU Grenoble Alpes, La Tronche
Hôpital Franco-Britannique, Levallois-Perret
Centre Oscar Lambert, Lille
ICM Val d'Aurelle, Montpellier
CHU de Poitiers, Poitiers
Gustave Roussy, Villejuif
Klinikum Aschaffenburg Medical Klinik IV, Aschaffenburg
Studienzentrale Gokos, Dresden
Universitätsklinikum Essen, Essen
Facharztzentrum Eppendorf, Hamburg
Oncoresearch Lerchenfeld, Hamburg
MVZ Mitte Leipzig, Leipzig
MZ Onkologie Velbert/Ratingen/Mettmann, Velbert
Clinica Oncologica Ospedali Riuniti di Ancona, Ancona
Santa Maria Goretti Hospital, Latina
Instituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
Azienda Ospedaliero-Universitaria Pisana, Pisa
AUSL-IRCCS of Reggio Emilia-Clinical Cancer Center, Reggio Emilia
Asst Valle Olona, Saronno
Hospital del Mar, Barcelona
La Paz University Hospital, Madrid
Hospital General Universitario de Valencia, Valencia
University Hospitals Birmingham NHS Foundation Trust, Birmingham
Harrogate & District NHS Foundation Trust, Harrogate
Imperial College Healthcare NHS Trust, London
University College London Hospitals NHS Foundation Trust, London
Collaborators (1)
Clinact
OTHER
Pierre Fabre Medicament
INDUSTRY